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Summary 
The surveillance of target cells by Natural Killer (NK) cells utilises an ensemble of inhibitory 
and activating receptors, many of which interact with major histocompatibility (MHC) class I 
molecules. NK cell recognition of MHC class I proteins is important developmentally for the 
acquisition of full NK cell effector capacity and during target cell recognition such that the 
engagement of inhibitory NK cell receptors and MHC class I molecules leads to the attenuation 
of NK cell activation.  Human NK cells have evolved two broad strategies for recognition of 
human leukocyte antigen (HLA) class I molecules: 1) direct recognition of polymorphic 
classical HLA class I proteins by diverse receptor families such as the Killer cell 
Immunoglobulin-like Receptors (KIR); and 2) indirect recognition of conserved sets of HLA 
class I-derived peptides displayed on the non-classical HLA-E for recognition by CD94-NKG2 
receptors. In this review, we assess the structural basis for the interaction between these NK 
receptors and their HLA class I ligands and, using the suite of published KIR and CD94-NKG2 
ternary complexes, highlight the features that allow NK cells to orchestrate the recognition of 
a range of distinctly different HLA class I proteins. 
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Introduction 
NK cells express an array of receptors belonging to a number of distinct families that recognize 
classical and non-classical MHC class I molecules and MHC class I-like molecules, including MIC-
A and -B and ULBPs (1). These recognition events are not only used to interrogate the health status 
of target cells but also play a developmental role by licensing NK cells that have inhibitory receptors 
binding self-MHC class I for the acquisition of full effector functions. In humans there are three 
“classical” MHC class I proteins, termed HLA-A, -B and -C, which display high degrees of 
polymorphism. The evolution of polymorphic HLA molecules has seen HLA-A and B allotypes 
accumulate variations within the antigen recognition site under pressure from T cell immunity, whilst 
HLA-C appears to have become specialized for NK cell immunity (2-4). While HLA polymorphism 
impacts peptide-loading and peptide repertoire to influence T cell receptor recognition (5), it also 
poses challenges for NK cell recognition of HLA class I molecules. 
 
There are at least two clear strategies employed by germline-encoded NK cell receptors for 
recognition of classical HLA class I molecules. The first involves targeting conserved regions of the 
HLA that display little polymorphism. For example, the Leukocyte Immunoglobulin-like Receptors 
(LIR) interact with the conserved 3 domain of HLA class I molecules and the β2m subunit (6).  The 
alternative molecular strategy for NK receptors involves recognition of the polymorphic regions of 
the HLA, which are in evolutionary terms, a moving target.  Perhaps unsurprisingly therefore, the 
MHC class I-reactive receptors utilised by NK cells differ across evolution.  Namely, the Ly49 
receptors expressed by rodent NK cells are homodimeric type II integral membrane receptors that 
have a C-type lectin-like fold (7). In contrast, in primates, these same functions appear to be mediated 
by the KIR family, which are of type I topology and possess extracellular domains that utilise an Ig 
fold (8, 9). Despite the differences in structure and topology, both receptor families utilise similar 
signalling pathways with inhibitory receptors possessing immunoreceptor tyrosine-based inhibitory 
motifs (ITIM), allowing for the recruitment and activation of phosphatases such as SHP-1, and 
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activating members associating with small immunoreceptor tyrosine-based activating motif (ITAM)-
containing adaptor proteins, including DAP12 (10-12). Furthermore, both KIR and Ly49 receptor 
families exhibit evidence of gene duplication, recombination and significant diversification that may 
be critical to retain the capacity to interact with the proteins encoded by highly polymorphic MHC-I 
loci (13, 14). 
 
Early studies showed that NK cell recognition of allogeneic target cells was dependent on HLA-C 
expression, with the HLA-C dimorphism (residues 77 and 80), which subdivide HLA-C molecules 
into C1 or C2 groupings, associated with protection from lysis by discrete subsets of NK cells (15-
18). Lanier, Parham and colleagues further identified a 70kD protein on a subset of NK cells, which 
recognised target cells expressing HLA-B allotypes with the Bw4 motif, a serological epitope 
spanning residues 77-83 (19, 20). Additionally, a third specificity was observed wherein a larger 
protein of 140kDa, a disulfide linked dimer, had specificity for HLA-A3 and the closely related HLA-
A11 (21, 22). Together these studies identified four distinct groups of HLA class I allotypes that were 
capable of inhibiting NK cell activation.  The receptors dictating this specificity were found to belong 
to a group of proteins, now known collectively as the KIRs. 
 
Killer cell Immunoglobulin-like Receptors 
Fifteen KIR genes have been identified in humans, encoded within the Leukocyte Receptor Cluster 
on chromosome 19, two of which are pseudogenes (23, 24). Remarkable genetic diversity exists in 
the KIR loci with polymorphism in individual genes as well as haplotypic variation in the gene copy 
number, both of which result in significant differences between individuals in the repertoire of 
expressed KIRs (25). The KIR proteins possess either two or three extracellular immunoglobulin (Ig) 
domains (termed D0, D1 and D2) giving rise to the KIR2D or KIR3D nomenclature (Figure 1) (26). 
Moreover while the prototypical KIR delivers inhibitory signals via the recruitment of phosphatases 
to long, ITIM-containing cytoplasmic tails (11), activating KIR possess shorter cytoplasmic regions 
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and a basic residue within their transmembrane region that facilitates their interaction with ITAM-
containing adaptors (10, 27, 28). Thus inhibitory KIR and activating KIR are termed L and S, 
respectively, in reference to the length of their cytoplasmic region, and hence signalling potential.  
 
Common features of KIR-HLA interactions 
To date, the structure of seven KIRs (2DL1, 2DL2, 2DS2, 2DL3, 2DL4, 2DS4 and 3DL1) (29-37) 
have been determined either in isolation or in complex with a HLA class I protein (Figure 2A-F). 
Each of the KIR ternary complexes shows the KIR positioned over the HLA class I molecule in a 
similar manner (Figure 2).  Namely, the D1 and D2 domains form a V-shaped interface, binding in 
an orthogonal manner with respect to the peptide-binding groove, positioning the D1 and D2 domains 
over the 1 and 2 helices of HLA, respectively. In addition to contacting the HLA class I molecule, 
the KIR is also situated over the C-terminal region of the peptide, indicative of peptide-dependent 
modulation of KIR interactions (29-31, 33). 
 
Analysis of the available KIR crystal structures shows the D1 and D2 domains to be arranged with 
slightly different hinge angles, some of which may alter upon complexation with the HLA class I 
ligand. In addition the hinge region also twists about the D1/D2 axis, thereby subtly impacting on the 
KIR-peptide(p)-HLA interface (Figure 2G-H).  Regardless of hinge flexibility, common to the KIR-
pHLA complexes, is a well-conserved binding footprint spanning residues 145 to 151 on the α2 helix 
of the HLA that interacts with the D2 domain of the KIR (Figure 3A-D and Table 1). Strictly 
conserved across all KIR structures is (i) a salt bridge between Arg145 and an aspartate (Asp135 
KIR2D; Asp 230, KIR3DL1) (29-31, 33); and (ii) a H-bond between Arg145 and a serine (Ser133, 
KIR2D; Ser228, KIR3DL1) (29-31, 33). Mostly conserved are the contacts to Ala149, Ala150, 
Lys146 and Arg151 of the HLA (29-31, 33). Accordingly, the region between residues 145 and 151 
on the α2 helix provides a conserved platform for KIR docking. 
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In contrast, the interactions between the D1 domain of the KIR and residues on the α1 helix of HLA 
class I are more variable and are primarily responsible for determining the specificity of individual 
KIR (discussed below) (Figure 4A-H). Notably, the C1/C2 determinants, and the Bw4 motif, are 
found within the region of the D1 contact zone. Moreover, within this region, the highly conserved 
HLA class I residues, Glu72, Arg75, Arg79 and Tyr84, can make variable contacts to the different 
KIR (29-31, 33). The polymorphic positions 76, 80 and 83 are of particular importance to establishing 
the molecular architecture of the HLA that enables each KIR to distinguish between distinct but 
structurally related ligands. 
 
KIR2DL recognition of HLA-C 
The structure of KIR2DL2 bound to HLA-C*03:04 (HLA-C1) (29) was the first KIR/HLA class I 
complex determined and when compared with the KIR2DL1-HLA-C*04:01 complex (HLA-C2) (30) 
allowed the molecular details underpinning the discrimination between KIR2DL1/2 for HLA-C1 and 
C2 to be ascertained. In comparison to KIR2DL1, the D1 domain of KIR2DL2 sits more to the N-
terminus of the 1 helix and forms more extensive and varied contacts (Figure 3) (29, 30). Notably, 
of the contacts made to the 1 helix, only those involving Phe45 on the D1 domain are maintained in 
both KIR2DL1 and KIR2DL2 (Table 1).  
 
Of the 16 residues in KIR2DL2 that contacted HLA-C*03:04, only two residues, positions 44 and 
70, differed in the C2-reactive KIR2DL1. Here, Met70 of KIR2DL2 made extensive contacts to the 
HLA class I 1 helix whilst the equivalent Thr70 of KIR2DL1 did not contact the HLA (Table 1, 
Figure 4A,B) (29, 30). While mutagenesis studies suggested residue 70 did not play a major role in 
defining KIR2DL receptor specificity, position 44 is of central importance (29, 38).  Notably, Met44 
of KIR2DL1, and the neighbouring residues create a negatively charged “specificity” pocket to 
accommodate the characteristic Lys80 of C2 allotypes (30) (Figure 4C,D). In comparison, Lys44 of 
KIR2DL2 constitutes the primary stabilising contact between KIR2DL2 and Asn80 of the HLA-C1 
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allotype.  Indeed, the substitution of Lys44 in KIR2DL2 for its methionine counterpart in KIR2DL1 
abrogated binding to C1 and was sufficient to convert the specificity of the mutant KIR2DL2 to C2 
(29, 38). The reciprocal Met44 mutation to lysine similarly converted the specificity of KIR2DL1 
(38). Residue 44 of both KIR2DL1 and KIR2DL2 contacts residue 80, the dimorphic position that 
distinguishes HLA-C1 (asparagine) from HLA-C2 (lysine). Thus, the specificity of KIR2DL1 and 
KIR2DL2 for HLA-C1 and C2 groups hinges on position 44 of the KIR molecule. 
 
Although there is little evidence that KIR2DL1 can bind C1 allotypes or that these allotypes can 
confer protection from lysis by NK cells expressing KIR2DL1, a number of studies have 
demonstrated that KIR2DL2, and its allelic variant KIR2DL3, can interact with C2 allotypes. 
KIR2DL2-Ig fusion proteins have been shown to bind beads coated with a number of C2 allotypes, 
albeit not to the extent that they bound C1 (39). Additionally, Pende and colleagues have shown that 
KIR2DL2/3 expression was sufficient to inhibit NK cell killing of both C2 positive leukemic blasts 
and 721.221 transfectants expressing C2 allotypes, suggesting that the low affinity KIR2DL2/3 
recognition of C1 allotypes was not without functional relevance (40). It will be of interest to establish 
the molecular basis underpinning the extent of promiscuity of the KIR2DL2/3 alleles towards the C2 
allotypes. 
 
KIR2DS recognition of HLA ligands 
While there is extensive functional, binding, mutagenesis and structural data probing the interactions 
of inhibitory KIR with their ligands, our understanding of activating KIR is less developed.  Despite 
very high levels of sequence identify, binding studies have typically found that the activating KIR 
either do not interact with HLA class I or bind with considerably lower affinity than their inhibitory 
counterparts (41, 42). The structures of KIR2DL/HLA ternary complexes provided a general 
framework for understanding the KIR2DS molecules as a result of these high levels of sequence 
identity. Not surprisingly the structure of KIR2DS4 was highly similar to that of KIR2DL, although 
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differences in some of the loop conformations between the 2DL/2DS4 structures provided an 
understanding of likely differences in ligand specificity (29, 37).  
 
The determination of the structure of KIR2DS2 bound to HLA-A*11:01 offered insight into how 
activating receptors can dock with HLA class I molecules (31) (Figures 3B, 4E,F). The overall 
binding interface of the complex was appreciably smaller than that of both KIR2DL ternary 
complexes. The contacts between KIR2DS2 and the 2 helix were predominantly conserved with 
KIR2DL, thereby implicating the specificity of the KIR2DS2 interaction being attributable to the D1 
contacts to the 1 helix (Figure 4E). Here, the D1 domain of KIR2DS2 docked more towards the C-
terminus of the 1 helix than any KIR solved to date. Consequently, the contacts by KIR2DS2 to the 
1 helix were more limited and had lower shape complementarity compared to the KIR2DL ternary 
complexes. (29-31). 
 
There are four amino acid differences between the extracellular domains of KIR2DS2 and KIR2DL2 
(positions 16, 45, 148 and 200), of which position 45 interacts directly with the 1 helix. Tyr45 is 
proposed to determine the specificity of KIR2DS2 since the introduction of a tyrosine at position 45 
of KIR2DL2 abrogated its capacity to bind HLA-Cw3 (43), whilst mutation of the Tyr45 in KIR2DS2 
to phenylalanine conferred the capacity to bind HLA-Cw7 (42). Interestingly while only the hydroxyl 
group of the Tyr45 side-chain makes contact to the 1 helix, this interaction does not drive 
recognition of HLA-A*11:01, as the Tyr45Phe mutation still recognised HLA-A*11:01, albeit with 
reduced affinity (31). Thus, Tyr45 likely operates via a steric mechanism to orient the D1 domain 
onto the binding interface. This working model is supported by the observation that a Tyr45Ala 
mutant abrogated binding (31). 
 
The observation that an activating KIR binds to common HLA-A allotypes (HLA-A*1101 and -
A*11:02) that are expressed at high levels is intriguing. To date, there is limited functional evidence 
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implicating KIR2DS2 recognition in NK cell activation, raising the possibility that the interaction is 
highly peptide dependent. Indeed, a better understanding of the significance of this KIR2DS2 
interaction awaits thorough assessment. 
 
KIR3DL1 interactions with HLA-Bw4  
KIR3DL1 and KIR3DL2 are proposed to be the evolutionary predecessors of KIR2DL1/2/3 (44). 
KIR3DL1 recognises HLA class I allotypes that contain the Bw4 motif, a feature of approximately 
one third of HLA-B allotypes (e.g. HLA-B27, HLA-B57) and 20% of HLA-A allotypes (e.g. HLA-
A24) (45, 46). To better understand the function of D0 domains and the impact of receptor 
polymorphism on ligand recognition, we determined the structure of KIR3DL1*001 bound to HLA-
B*57:01 presenting the self-peptide LSSPVTKSF (LF9) (33) (Figures 2C,D, 3C). Like the KIR2D 
receptors, KIR3DL1 docked in an orthogonal manner relative to the peptide-binding groove, and 
created two spatially distinct interfaces. The D0 domain bound to two conserved loops on HLA-
B*57:01 (residues 16-19 and 88-92) (33). Residues 16-19 of HLA-B*57:01 are conserved across 
HLA-B allotypes, and most HLA-A allotypes, suggesting that the D0 domain of KIR3DL1 does not 
confer allotype specificity, but enhances MHC class I binding irrespective of allotype, echoing a 
concept proposed by Khakoo and colleagues based on functional studies (33, 47). Taken together the 
D0 domain appears to act as an innate sensor of MHC class I proteins. 
 
The second HLA-B*57:01 binding site was generated by the D1 and D2 domains of KIR3DL1 that 
were positioned over the 1 and 2 helices respectively, akin to the mode of binding observed for 
KIR2D receptors (Figure 4G,H). In addition to the common contacts made to residues 142-151 of 
the HLA class I 2 helix, KIR3DL1 also contacted Tyr84 and Arg83 of HLA-B*57:01, the latter a 
defining residue of the Bw4 motif (33). Further HLA class I contacts included residues 72 and 76, 
which are also a feature of ligand binding by KIR2DL1 and KIR2DL2  (Table 1) (33). 
 
 10 
One of the primary features of the KIR3DL1/HLA-B*57:01/LF9 interface was the presence of a 
series of charged interactions that link three loops formed by residues 165-167 from the D1 domain, 
199-200 located in the D1/D2 linker region and 278-282 from the D2 domain (Table 1) (33).  Pivotal 
to this network was Glu282 of KIR3DL1, which formed a critical salt-bridge to Lys146 but whose 
positioning appeared dependent on a series of additional KIR residues including Ser279, Tyr200 and 
Phe276. Consistent with this, alanine scanning mutagenesis demonstrated that mutation of Glu282 
along with Tyr200, Phe276 and Ser279 all impacted binding to HLA-B*57:01 (33).  
 
The D1 domain of KIR2D receptors manifestly dictates HLA binding specificity, with residues at 
positions 44 and 45 intercalating into the 1 helix. By comparison, the binding interface of the D1 
domain of KIR3DL1 was non-ideal, lacking both charge and shape complementarity (33).  To probe 
this further, alanine-scanning mutagenesis was performed on both sides of the interface and revealed 
somewhat contrasting effects. For example, alanine mutations to KIR residues His278 and Leu166 
had little impact on binding to HLA-B*57:01 whereas mutation of the HLA-B*57:01 residues that 
these residues contact, Arg83 and Ile80, abrogated binding (33). Further analyses of the molecular 
micro-architecture of the Bw4 motif suggested a salt-bridge between Arg83 and Glu76 that locked 
the position of the acidic side-chain was critical in allowing KIR3DL1 recognition (48).  Notably, in 
HLA-Bw6 allotypes, this salt bridge is absent as a consequence of the presence of a glycine at position 
83, providing an explanation for why KIR3DL receptors do not bind Bw6 allotypes (48).  
 
The Bw4 motif is polymorphic, with a dimorphism at residue 80 (isoleucine or threonine) influencing 
protection of target cells from NK cell mediated lysis. Early studies by Cella et al. suggested that 
position 80 modulated the strength of KIR3DL1 interactions since Bw4+ alleles with Ile80 appeared 
to be more potent inhibitors of target cell lysis by KIR3DL1+ NK cells (49). This notion gained further 
credence as genetic studies linked the presence of certain KIR3DL1 alleles and HLA-Bw4/Ile80 
allotypes with delayed progression to AIDS (49, 50). In agreement with this, the mutation of Ile80 to 
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threonine in HLA-B*57:01 markedly diminished the strength of its interaction with KIR3DL1 (33). 
Moreover, the ternary complex of KIR3DL1 bound to the HLA-B*57:01.I80T mutant showed that 
this substitution resulted in the loss of a direct KIR contact that was, in part, replaced by a network 
of water-mediated interactions (51). However the data pertaining to KIR3DL1 recognition of Bw4 
allotypes that encode a threonine is varied. For example, comparison of the recognition of HLA-B27 
subtypes by NK clones revealed only HLA-B*27:02 (Ile80) to be susceptible to lysis whereas other 
HLA-B27 subtypes (Thr80) were resistant (52). Indeed in this study the mutation of Thr80 to 
isoleucine in HLA-B*27:05 resulted in impaired protection (52). Together these data are indicative 
of an underlying complexity, likely arising from differences in allotype associated peptide repertoires, 
together with receptor polymorphism. 
 
KIR3DS1 recognition of HLA ligands 
KIR3DS1 is a variant of KIR3DL1, separated by a unique set of polymorphisms. These include a 
stop codon that results in the loss of the inhibitory ITIM cytoplasmic motifs and the introduction of 
a charged amino acid in the transmembrane region that facilitates the interaction with DAP12 to result 
in switched signalling capacity (53). In addition to these changes, there are discrete polymorphisms 
in the extracellular domains that impact on the capacity of KIR3DS1 to bind HLA class I molecules. 
Two of these, S58G and V92M in the D0 domain, are not commonly occurring polymorphisms 
among KIR3DL1 molecules.  Four additional polymorphisms are found in the D1 and D1-D2 loop 
region of KIR3DS1 (G138W, P163S, L166R and L199P) (Table 2) (54). Together these changes 
confer a broad lack of HLA-Bw4 reactivity by KIR3DS1; in cellular assays KIR3DS1 is not activated 
by cells expressing HLA-Bw4 allotypes (55, 56) nor does it appear to bind HLA-Bw4+ tetramers 
(57).   
 
The failure of KIR3DS1 to interact with HLA-Bw4 molecules can be attributed to the D1/D2 
polymorphisms since the introduction of any single KIR3DS1-like residue into KIR3DL1 
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significantly reduced or abolished binding to HLA-A*24:02 (58). The arginine at position 166 in the 
D1 domain of KIR3DS1 plays a dominant role in limiting binding to Bw4+ allotypes, as the 
introduction of L166R mutations into KIR3DL1 was found to abrogate binding to a broad panel of 
HLA tetramers bearing the Bw4 epitope (55). Furthermore, structural modelling based on the 
KIR3DL1/HLA-B*57:01 structure suggested the introduction of an arginine at 166 would result in 
both steric and charge clashes with Arg83 of the Bw4 motif itself (55).  
 
Although there is little direct evidence that KIR3DS1 binds HLA-Bw4 molecules there is genetic 
data suggesting that KIR3DS1, in combination with Bw4/Ile80, plays a role in the control of HIV 
infection, delaying progression to AIDS (59) as well as protection from opportunistic infections (60). 
Supporting these observations, Alter has shown that that KIR3DS1+ NK cells expand in HIV-infected 
Bw4+ donors and in in vitro assays KIR3DS1+ cells can inhibit HIV replication and kill Bw4+ HIV-
infected cells (61-63). To explain the discrepancy between the binding and functional data, it was 
proposed that KIR3DS1 may have a very restricted ability to bind to HLA class I, and that the 
presence of specific peptides when bound to HLA-Bw4, would enhance KIR3DS1 recognition. 
Indeed, we were able to identify a number of HLA-B*57:01-restricted peptides that permitted weak 
KIR3DS1 interactions (55). However, it remains unclear what pathogens or immune stress condition 
would have driven the evolution of such a peptide-restricted system and how highly specific 
recognition of peptide-MHC complexes by KIR3DS1 would be selected for in populations with 
highly diverse HLA class I molecules.  
 
Peptide modulates KIR recognition of HLA class I allotypes 
While it is evident that KIRs have specificity for distinct HLA class I allotypes, the HLA class I 
proteins expressed on any given cell are themselves quite heterogeneous as a result of their association 
with a diverse repertoire of peptides. Although the peptide forms a critical part of the ligand 
recognized by the TCR (5), the precise role of peptide and, in particular, how complex peptide 
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repertoires collectively act to modulate NK cell recognition of HLA class I molecules is unclear.  The 
culture of TAP-deficient cell lines with individual synthetic peptides to create homogeneous cell 
surface expressed peptide-HLA class I complexes have demonstrated that: a) peptide was required 
for NK cell recognition of HLA-B*27:05, HLA-Cw4 and HLA-C*03:04 by their respective KIR (64-
67) and b) there was significant variation in the capacity of different peptides to facilitate interactions 
between KIR and HLA class I proteins. Perruzi and colleagues made a systematic series of 
substitutions in the HLA-B*27:05-binding peptide FRYNGLIHR to show that P7 and P8 were 
important for recognition. Specifically, substitution of P8 with histidine, alanine and valine at P8 
were able to inhibit target cell lysis whereas the presence of a charged residue at this position 
abrogated protection (64). Furthermore, substitution of a histidine into an otherwise non-permissive 
peptide could also protect TAP-deficient target cells expressing HLA-B27 from lysis (64). 
Substitutions at P8 of the HLA-Cw4 binding peptides were similarly able to abrogate KIR2DL1 
recognition of target cells (65).  
 
Structural studies have provided insight into understanding why some peptides support KIR 
interactions whereas others abrogate recognition (Figure 5A-D). The docking of the D1 and D2 
domains over the C-terminal region of the peptide is entirely consistent with the functional data 
implicating P7 and P8 as important for KIR recognition. In the KIR2DL2/HLA-C*03:04 complex, 
direct contacts were made between the receptor and the GAVDPLLAL peptide loaded onto HLA-
C*03:04: Leu7 interacted with Leu104 of KIR2DL2 whilst Ala8 bound Gln71 (Figure 5B) (29).  
Proximal to P8 were KIR2DL2 residues that placed size constraints on the side-chains that would be 
permissive (29).  Accordingly, substitution of a serine at P8 was tolerated, but substitution to larger 
residues such as tyrosine and lysine abrogated binding of HLA-C*03:04 by KIR2DL2 (29). 
 
KIR2DL1 made more limited contact with the peptide QYDDAVYKL in complex with HLA-Cw4, 
with Leu9 making a water-mediated contact to Glu187 of KIR2DL1 (Figure 5A) (30). The KIR2DL1 
 14 
residues surrounding P8 of the peptide, however, created an electronegative, polar surface that 
explained the lack of tolerance for acidic amino acids in this position (30, 65). Despite having an 
affinity for HLA-C that was ~3.5 times lower than that of KIR2DL1, KIR2DS1 also shared similar 
peptide preferences, with P8 substitutions of Tyr7Ala, Lys8Asp and Lys8Glu in the QYDDAVYKL 
peptide all abrogating KIR2DS1 binding (Figure 5C) (41). 
 
The role of peptide in regulating the interaction of KIR3DL1 with its ligands has been investigated 
in several contexts. The contribution of peptide to NK cell recognition of HLA class I molecules was 
realised when mutations within the peptide binding cleft of HLA-B*27:05 (residues 45, 95 and 116) 
impacted protection from lysis by NK clones (67). Similarly, comparisons of NK cell recognition of 
HLA-B*51:01 and HLA-B*15:13 also suggested that HLA class I recognition by KIR3LDL1 was 
sensitive to changes in buried residues that interact with peptide (46). Structural studies of KIR3DL1 
bound to the HLA-B*57:01/LF9 complex showed that Leu166 of KIR3DL1 directly contacted the 
serine at position eight of the peptide (Figure 5D) (33). Substitutions of phenylalanine or histidine at 
position eight of the LF9 peptide were tolerated by KIR3DL1, with their bulky side chains 
accommodated by a large solvent-filled cavity surrounding this position (33, 51). Further the P8 
arginine substitution impaired binding of KIR3DL1 while the presence of a glutamate at this position 
essentially abrogated KIR3DL1 binding, consistent with earlier work from Peruzzi and colleagues 
(33, 51, 64).  Somewhat surprisingly the presence of small hydrophobic amino acids substituted at 
P8 of the LF9 peptide also had a detrimental impact on KIR3DL1 binding. The underlying mechanism 
remains unclear but presumably reflects disruption of the interface (33, 51). Consistent with this, in 
studies of HLA-B*51:01 the sequence of the HLA class I bound peptide has been suggested to impact 
upon the conformation of the Bw4 motif as assessed by changes in the reactivity of monoclonal 
antibodies (68). While the molecular interactions underpinning these changes are unclear, structures 
of HLA-B27 and HLA-B57 have shown that P8 can interact with a number of residues proximal to 
the Bw4 motif (64, 69-72). It is conceivable that the presence of a charged side-chain at this position 
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may disrupt the internal salt-bridge between Glu76 and Arg83 of the Bw4 motif, which in turn could 
reposition Glu76 and impair KIR3DL1 docking (48, 69). 
 
The importance of peptide in KIR/HLA class I interactions has often been assessed in binding assays 
using HLA class I tetramers that are complexed with viral peptides or variants (51, 73-75). Studies 
of a naturally occurring HIV peptide variant (TW10) have shown that recognition of HLA-B*57:03 
carrying a peptide with a glycine to glutamate mutation at the penultimate residue abrogated 
KIR3DL1 binding and HLA-B*57:01 binding was similarly lost when an alanine or aspartate was 
present (74, 75). The recognition of HLA-B*57:01 and HLA-A*24:02 by KIR3DL1 also varied with 
different HIV peptides suggesting that NK cell recognition of HIV-infected cells could potentially be 
influenced by peptide (74). Additionally studies by Alter identified polymorphisms in a number of 
HIV proteins that resulted in enhanced binding of KIR-Ig fusion proteins and decreased degranulation 
of KIR2DL2+ NK cells (63). While the data imply that the virus can adapt in order to potentiate 
inhibitory signalling, the underlying mechanism remains unclear.  Both binding and functional studies 
have shown that there is significant variation in the capacity of peptides to support the interaction 
between KIR and HLA class I proteins, however the proportion of peptides on the cell surface that 
can actually mediate KIR interaction is unknown. Indeed, this may be a major factor in the relative 
potency of some HLA class I allotypes to inhibit NK cell activation. Similarly, whether or not 
infection or malignant transformation induces changes in peptide repertoire that can impact KIR-
mediated recognition of HLA class I expressed by target cells requires further investigation. In this 
context, it is interesting to note that relatively few HLA-B27-binding peptides could confer protection 
whereas the frequency of peptides that could bind HLA-C*03:04 and confer protection was somewhat 
higher albeit that the total number of peptides assessed to date is small (66, 67). New strategies to 
both identify and quantify the endogenous peptides bound to different HLA class I allotypes 
necessary for inhibitory signalling are needed. 
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KIR polymorphism: the case of KIR3DL1  
A feature of several of KIR genes is the acquisition of a significant number of polymorphisms. In the 
case of KIR3DL1, over 110 alleles have presently been described, generating 66 distinct allotypes 
(76). Early studies using transduced NK cell lines and primary NK cell cultures showed that 
KIR3DL1 polymorphism modulated the extent of cellular activation after engagement of HLA 
ligands (77, 78). Numerous studies have now shown that such allelic variation influences the 
frequency of KIR3DL1 expression (79), cell surface expression levels (80, 81) and ligand binding 
(58, 73, 77). Indeed, KIR3DL1 polymorphism influences the variable recognition of Ile80- versus 
Thr80-containing Bw4 allotypes and potentially impacts the general hierarchies within HLA-Bw4 
molecules bound by KIR3DL1 allotypes (19, 20, 49, 51, 52, 77).   
 
Genetic analyses have subdivided KIR3DL1 sequences into two allelic lineages (*015-like and *005-
like), which, along with a third encoding the activating KIR3DS1 alleles, are present in all populations 
studied to date and appear to be maintained via balancing selection (54).  Seven amino acid 
differences distinguish the *005 and *015 canonical sequences, two in the signal sequence, three in 
the D0 domain and two in the D1/D2 domains (Table 2) (54).  Additional polymorphisms are found 
throughout the whole KIR3DL1 molecule, with a higher number occurring in the extracellular 
domains, presumably selected under evolutionary pressure (54).  These positively selected residues 
include the HLA contacts, residues 138 and 166 from the D1 domain and residue 199 from the D2 
domain (33, 54).  
 
Polymorphisms in the D0 domain can influence the strength of binding of KIR3DL1 allotypes to 
HLA-Bw4 molecules (58). A cluster of polymorphic residues in the D0 domain (position 2, 47 and 
54) differ between the *015-like and *005-like lineages (Table 2). The D0 configuration in *005 
promotes stronger binding to the Bw4+ HLA-A*24:02 and the introduction of a *015-like D0 domain 
into *005 impaired this interaction (58). The *001 allotype, for which the crystal structure was solved, 
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is the result of a recombination event between the *015-like and *005-like lineages and combines the 
strong D0 domain of *005 with the D1 and D2 domains of *015.  This recombinant generates a KIR 
receptor with very strong ligand interactions (58) and with potent inhibitory capacity (82). Residues 
2, 47 and 54 do not contact the HLA directly, nor are they predicted to affect HLA binding (33), yet 
their variation within this ‘innate HLA sensor’ domain impacts recognition. There is as yet no clear 
explanation for these effects but it is tempting to speculate that at least some of these polymorphisms 
affect clustering or the capacity of the receptor to form higher order complexes. 
 
Position 283 in the D2 domain is another dimorphic residue that differs between the two inhibitory 
KIR3DL1 families.  The presence of Leu283, as found in *005-like allotypes, has been associated 
with reduced binding to HLA-A*24:02/nef tetramers (58) whilst binding to HLA-Bw4/Thr80 
allotypes, including HLA-B*27:05 and HLA-B*44:02, was increased as compared to binding by 
*015-like molecules that encode a tryptophan at this position (51). Indeed, while Trp283-encoding 
KIR3DL1 allotypes (*015, *001) show a distinct preference for HLA-Bw4/Ile80 allotypes over HLA-
Bw4/Thr80 allotypes, *005 binds both HLA subtypes equally well (51). Overall, the *005-lineage 
appears to have a broader specificity for HLA-Bw4+ molecules (51, 73).  
 
In addition to HLA subtype discrimination, the presence of Leu283 has been linked to altered peptide 
permissiveness for HLA-B*57:01 peptide complexes. KIR3DL1*005 was more tolerant of a P8 
leucine substitution and less sensitive to P8 arginine substitution than KIR3DL1*001 (51). While the 
introduction of a negatively charged aspartate residue into the HLA-B*57:01 restricted HIV gag 
epitope TW10 (TW10 G9D) decreased binding to *001 and *015 allotypes, *005 was more tolerant 
of this substitution (51). Recognition of a broader array of peptides by KIR3DL1*005 was also 
suggested by the work of Thananchai et al, who found that it bound to a greater number of HLA-
A*24:02 and HLA-B*57:03 peptide complexes than other KIR3DL1 allotypes (73). This modulation 
in ligand specificity of Leu283 allotypes has been postulated to be a result of a conformation change 
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in the D1-D2 interface. Residue 283 falls in the hinge region between the two domains and the 
substitution of the bulky hydrophobic amino acid tryptophan for leucine may impact the relative 
juxtapositioning of the D1 and D2 domains (51, 58, 73).   
 
Polymorphic differences within a lineage can also impact KIR3DL1-HLA class I interactions. In 
comparing KIR3DL1*002 and *007, both *015-like alleles, Carr et al. identified two polymorphic 
positions that were responsible for the reduced inhibition of cells expressing the *007 allotype: 
Arg238Gly in the D2 domain and Ile320Val in the transmembrane domain (78). Position 238 is distal 
from the ligand binding face of KIR3DL1, which is a common feature of many of the extracellular 
polymorphisms (33), while the transmembrane polymorphism is unlikely to influence ligand binding.  
Instead, the variable functional outcomes with different KIR3DL1 allotypes could be the result of a 
number of factors including the inhibitory signalling capacity, affinity for HLA class I ligand, 
clustering, cell surface expression levels/stability and peptide sensitivity of the KIR. Delineating these 
contributions will help clarify the significance of KIR3DL1 polymorphism in genetic association 
studies linking, allelic variation on the outcome of HIV infection (50), as well as in transplant settings. 
 
 
 
D0-D2 KIR: more questions than answers 
Whilst the consecutive (D0)-D1-D2 arrangement of KIR2DL1/2/3 and KIR3DL1/2 molecules results 
in comparable structural and binding motifs, the D0-D2 configuration of KIR2DL4 and KIR2DL5 
has resulted in distinctive structural features. Both KIR2DL4 and KIR2DL5 differ from archetypal 
KIRs in signalling potential. KIR2DL5 contains both an ITIM and an immunoreceptor tyrosine-based 
switch motif (ITSM), the functional consequences of which are unclear although the receptor 
nevertheless retains inhibitory potential (83, 84).  KIR2DL4 encodes both an ITIM in its cytoplasmic 
region and an arginine residue in the transmembrane domain that facilitates pairing with the ITAM-
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containing adaptor molecule FcR-γ (85). Although KIR2DL4 can transmit inhibitory signals when 
the transmembrane arginine is mutated (84, 86), the predominant functional output of KIR2DL4 is 
activation as seen by the strong IFNγ secretion and limited cytotoxicity in antibody-mediated cross-
linking experiments (87, 88). Indeed more recently, KIR2DL4 signalling has been proposed to initiate 
an activation program typical of senescent cells (89).  
 
Understanding ligand recognition and signal transduction by KIR2DL4 is further complicated by its 
largely endosomal localisation, a property dependent on its ectodomains (88, 90). The resolution of 
the structure of KIR2DL4 showed that like other KIR2D receptors, the D0-D2 domains of KIR2DL4 
adopted a “V” architecture, yet with a less acute hinge angle of ~85° relative to that between the D1 
and D2 domains in other KIR (34). Most notably, however, unlike other KIR receptors, which exist 
as monomers in solution, KIR2DL4 was observed as a tetramer (Figure 2) where the concentration-
dependent oligomerisation was driven by the self-association of the D0 domains (34). The 
oligomerisation interface utilised residues that previously featured in the interaction between 
KIR3DL1 and HLA-B*57:01(33, 34). Structural comparison between KIR2DL4 and KIR3DL1 
demonstrate that while the D2 domains overlay very closely, the D0 domains deviate significantly. 
Furthermore, KIR2DL4 has an unusual disulfide pairing between Cys10 and Cys28, whereas Cys28 
is paired to Cys74 in all other KIR D0 domains. In the context of KIR2DL4, the D0 domain appears 
to function as a ‘self-association module’ rather than an ‘innate HLA sensor’ as for KIR3DL1.  
 
Whether ligand binding by KIR2DL4 and KIR2DL5 utilises analogous residues to KIR2DL1/2/3 and 
KIR3DL1 is presently unknown. KIR2DL4 does not appear to bind classical HLA class I molecules 
with a recent study reporting no binding of recombinant KIR2DL4 to a panel of 100 HLA class I 
allotypes (34). Association between KIR2DL4 and the non-classical MHC molecule HLA-G, 
however, have been reported with a KIR2DL4-Ig fusion protein binding to HLA-G expressing cell 
lines (91-93). Similarly soluble HLA-G has been shown to stimulate cytokine production from resting 
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NK cells (88).  However a number of additional studies have failed to observe an interaction between 
KIR2DL4 and HLA-G either via direct binding or functional approaches (34, 94-96). Alternatively, 
heparanated proteoglycans have been proposed as KIR2DL4 ligands, found to interact with the D0 
domain and affect endosomal uptake of KIR2DL4 independently of HLA-G (97).  Solution phase 
studies demonstrating unambiguous interactions between purified KIR2DL4 and KIR2DL5 with their 
ligands are important for refining our understanding of the functions of KIR2DL4 and KIR2DL5 and 
ultimately their physiological roles. Given the impact of oligomerisation on membrane trafficking, 
structural insights into the organisation of KIR2DL4 into higher order oligomers may open new 
avenues of investigation into these distinctive KIR.  
 
CD94-NKG2 recognition of HLA-E 
An alternative mechanism for NK cell recognition of HLA class I molecules is mediated through the 
heterodimeric CD94-NKG2 receptors that bind the non-classical HLA class I molecule, HLA-E (98, 
99). Unlike the polymorphic classical HLA class I molecules, HLA-E is essentially dimorphic, with 
two alleles varying only at position 107 each being present in most populations at frequencies of 
approximately 0.5 (100) (101).  HLA-E is the most evolutionary conserved of the HLA class I 
molecules with the murine Qa-1b molecule now considered to be a direct ortholog (102, 103).  
Transfection of 721.221 cells that express HLA-E but not endogenous HLA-A, -B or -C with 
plasmids encoding some (but not all) HLA class I alleles protected the transfected cells from lysis by 
NK cells expressing CD94-NKG2A (104, 105). This protective effect was dependent on residues 3-
11 of the HLA class I allotype (98, 99). HLA-E has a preference for binding peptides with a 
methionine at P2 and leucine at P9 (106), features that are largely conserved across the leader 
sequences of HLA class I proteins, the notable exceptions being a group of HLA-B allotypes that 
possess a threonine at P2 and HLA-E itself (98). Moreover studies from Braud and colleagues 
revealed the loading of peptides into HLA-E was largely TAP-dependent (107). Thus the interaction 
of HLA-E bound to HLA class I-derived leader sequence peptides with CD94-NKG2A represents a 
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means by which NK cells can indirectly monitor the “global” expression of classical HLA class I 
proteins together with the integrity of the antigen processing machinery.  
 
The CD94-NKG2 receptors consist of an invariant CD94 polypeptide disulfide-bonded to a member 
of the NKG2 family, most typically NKG2A or NKG2C (108-110). Like many immunoreceptor 
families, there are both inhibitory and activating forms of the NKG2 subunit (111, 112). NKG2A is 
the only gene encoding an inhibitory receptor and directs expression of both NKG2A and its 
alternatively spliced variant NKG2B (112,113). While there are a number of genes encoding 
activating NKG2 subunits, as a group they have a limited capacity to assemble with CD94. Notably 
NKG2D does not associate with CD94 but forms a homodimeric receptor that recognises stress-
induced ligands (109, 114, 115). Of the remaining activating isoforms, CD94-NKG2C heterodimers 
are expressed at the cell surface, but little evidence exists to suggest that NKG2E and -F form 
functional heterodimers with CD94 at the cell surface, although NKG2H, an alternatively spliced 
variant of NKG2E, has been identified on a T cell clone (116-118). In contrast to NKG2A, the 
NKG2C subunit lacks an ITIM but like activating KIR is associated with adaptor protein DAP12 and 
can trigger cellular activation (119). 
 
The ternary CD94-NKG2A/HLA-E structure yielded valuable insight into the mode of ligand 
recognition, with little conformational change evident in either HLA-E or CD94-NKG2A when 
compared to their binary structures (Figure 6) (120, 121). Somewhat surprisingly, the CD94 subunit 
dominated the contacts with HLA-E, indicating that the primary function of the CD94 subunit was 
ligand binding (120-122). However, as CD94 lacks the capacity to signal, the NKG2A subunit 
dictated signalling following recognition of HLA-E.  
 
CD94-NKG2A bound HLA-E in a diagonal orientation positioned toward the C-terminal end of the 
peptide-binding cleft (121) (Figure 6A-C). In contrast to the KIR/HLA complexes, CD94-NKG2A 
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interacted with a greater area of the bound peptide (121). The structures of HLA-E bound to leader 
peptides from HLA-B7 (VMAPTRVLL) (123, 124), HLA-G (VMAPTRLFL) (125), HLA-Cw7 
(VMAPRALLL)(125), HLA-C*03:04 (VMAPRTLIL) (126) and HLA-B27 (VTAPRTLLL) (124) 
showed that each peptide sits in an analogous manner within the cleft, with a more extensive set of 
contacts distributed along the length of the peptide bound to HLA-E than is typical for classical MHC 
class I (123). The relatively strict requirements for peptide to bind HLA-E significantly constrain the 
number of peptides capable of supporting its interaction with CD94-NKG2 receptors. 
 
Surface plasmon resonance analyses demonstrated the interaction between CD94-NKG2A and 
peptide-laden HLA-E to be typically 0.5-20µM, similar to that reported between inhibitory KIR2DL1 
and KIR2DL2/3 with C2 and C1 allotypes respectively (29, 120, 127-129). Indeed, the sequence of 
these HLA-E bound peptides was critical for the interaction with CD94-NKG2A, as the receptor 
made contacts with P5, P7 and P8 (Figure 6D). The P5-Arg sat in a cleft formed between CD94 and 
NKG2A (121); P8-Phe was positioned in a pocket formed by CD94, consistent with binding studies 
showing that P8 could modulate the affinity of the interaction (120, 127, 128); Gln112 of CD94 
played a key role in determining the peptide specificity of the receptor, intercalating between the P5 
arginine and the P8 phenylalanine and making main chain contacts with threonine at P6. Together 
these interactions explain why hydrophobic residues such as leucine, valine and isoleucine, all of 
which are present in distinct HLA class I allotypes, were tolerated at P8 and why substitutions of 
arginine at P5 abrogated receptor binding (106).  More broadly, the complex illustrated the central 
role the peptide plays in interactions with both HLA-E and the NK receptor, providing in essence a 
dual layer of specificity. 
 
While the structure of CD94-NKG2C is not yet determined, the ectodomain of NKG2C receptor 
shares high levels sequence similarity with NKG2A (112). Despite this, the CD94-NKG2C 
heterodimer had a six to eight-fold decrease in affinity for HLA-E compared to CD94-NKG2A, 
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regardless of the peptide bound to HLA-E (120, 128). Indeed similar differences between CD94-
NKG2A and -NKG2C binding were also evident when HLA-E was bound to peptides derived from 
variants of the cytomegalovirus (CMV) UL40 protein, which mimic HLA leader sequences (130, 
131). While this could reflect direct but differing contributions of the NKG2 subunits to the 
interaction, structural analyses and mutagenesis studies also suggest that the reduced affinity of 
CD94-NKG2C for HLA-E may stem from NKG2 differences at the heterodimer interface that have 
the potential to impact the conformation of CD94 (120, 121).  
 
There is now a wealth of data linking elevated CD94-NKG2C expression with CMV infections,(132-
134). For example in vitro studies showed that culture of NK cells with CMV-infected fibroblasts 
induced an expansion of NKG2C+ cells (132-134). The mechanism responsible appears to involve 
ligand recognition since silencing of HLA-E expression in infected fibroblasts impairs the induction 
of NKG2C (135). The high degree of sequence identity shared between the ectodomains of NKG2A 
and NKG2C, combined with structural and binding data that show both a dominant role for CD94 
and the extensive peptide constraints required to permit HLA-E binding to CD94-NKG2A, suggest 
that very few peptides will have the capacity to engage the activating receptor (112, 121).  Rather, 
signalling via CD94-NKG2C may depend on the overall cell surface level of HLA-E which in the 
context of infection may be upregulated due to pro-inflammatory cytokines such as IFN. Further 
molecular definition of how CD94-NKG2C interacts with its ligands is required to better understand 
the significance of the expansion of NKG2C+ cells following CMV infection and its relationship with 
their elevated functional capacity (136, 137). 
 
Conclusions & Future Directions 
Structural studies have provided major insights into the molecular interactions underpinning NK cell 
recognition of HLA class I proteins and the critical determinants of receptor specificity. Indeed this 
approach has revealed that recognition is largely focused on elements conserved across large groups 
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of HLA class I allotypes. This strategy is a feature of the interaction of both KIR and CD94-NKG2 
receptors with their respective ligands, in the case of KIR utilising a conserved platform on the 2 
helix of classical HLA class I proteins while CD94-NKG2 receptors engagement is dependent on 
conserved peptides from HLA class I-derived signal sequences. 
 
Unlike T cells, individual NK cells frequently express multiple MHC class I reactive receptors, and, 
in the case of KIR, bind multiple HLA class I allotypes that typically associate with thousands of 
different peptides within any given cell. This in essence generates a highly complex recognition 
matrix, dependent not only on the expression of multiple distinct receptors on the NK cell but also on 
the number and type of ligands expressed by the target cell. It is unclear if the inhibitory receptors all 
act in a cumulative manner, being recruited to the same immune synapses with “additive” signalling, 
or whether differences in ligand affinity, membrane mobility and/or capacity to cluster results in the 
formation of distinct “microclusters” with their respective HLA class I ligands.  
 
Critical to unravelling NK cell receptor interactions with HLA class I ligands is an understanding of 
the contributions of the HLA-bound peptide.  The KIR/HLA system necessarily requires a degree of 
tolerance for different peptides in the receptor/ligand interface since KIR are specific for multiple 
HLA class I allotypes which typically have additional polymorphisms in the peptide-binding groove 
that may impact on the peptide repertoire. In contrast to KIR ligands, the minimal allelic variation 
within HLA-E has allowed for the evolution of a recognition mechanism that is exquisitely peptide 
specific. Somewhat paradoxically, the strict peptide features that allow both binding to HLA-E and 
interaction with CD94-NKG2 receptors has provided a defined molecular target that can be exploited 
by pathogens via molecular mimicry.  
 
A number of distinct peptide-HLA class I complexes, either in the form of tetramers or as cell surface 
complexes expressed on TAP-deficient target cells, have been shown to bind KIR or inhibit NK cell 
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activation (64, 67, 73, 74), yet it remains unclear whether these peptides have sufficient potency to 
transduce inhibitory signals in an in vivo context. Are the peptides that actually drive inhibitory 
signalling a much smaller subset of those found to interact in tetramer binding studies? Alternatively, 
inhibitory signalling may stem from cumulative interactions with a large number of different peptides 
bound to a given HLA class I allotype. Such questions are important for at least two reasons.  Firstly, 
the capacity of different HLA class I allotypes to bind peptides that promote high affinity interactions 
may drive their relative inhibitory potency. HLA class I allotypes in which 10% of peptides support 
high affinity interactions with KIR may effectively appear to be better KIR ligands than those where 
only 1% allow for such interactions. Secondly, if the proportion of peptides that actually promote in 
vivo interactions is small, then there is an increased potential for infection-induced changes to the 
peptide repertoire modulating KIR-mediated recognition of HLA class I.  
 
While interactions between individual KIR and HLA class I allotypes have been assessed extensively, 
in vitro studies are suggestive of significant differences between allotypes that all belong within 
defined KIR ligand groups. For example, HLA-Cw7 has been suggested to be a “strong” ligand for 
KIR2DL2/3 compared to other C1 ligands (138). Given the apparent conservation of contact residues 
across all C1 ligands, understanding of the features, beyond simply the presence of an Asn80, that 
modulate the strength of these interactions may be important. Furthermore these more subtle but 
potentially significant differences may extend beyond classical KIR/ligand pairs. For example, while 
KIR2DL2 preferentially interacts with C1 allotypes, it nevertheless has the capacity to recognise at 
least some C2 allotypes. In C1/C2 heterozygous individuals, the extent to which KIR2DL2 recognises 
C2 allotypes, and indeed whether only a subset of C2 allotypes can interact and/or augment signalling, 
remains ill-defined. Understanding the extent to which allelic variation in HLA class I molecules 
impacts KIR recognition is critical to understanding the increasing number of genetic association 
studies linking the presence of particular KIR and HLA class I genes with disease outcomes. 
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Figure Legends: 
 
Figure 1: Members of the KIR family and their HLA class I ligands. Members of the KIR family are 
divided into activating and inhibitory receptors based upon the length of their cytoplasmic tail (long, 
L, or short, S).  Long-tailed inhibitory receptors encode one or two immunoreceptor tyrosine-based 
inhibitory motifs (ITIM) within their cytoplasmic tail, with KIR3DL2 and KIR2DL5 containing 
immunoreceptor tyrosine-based switch motif (ITSM)-like motifs.  Short-tailed activating receptors 
contain a charged amino acid within their transmembrane region, which facilitates association with 
immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor proteins such as DAP12 
or FcRγ. The extracellular region of KIR is composed of two or three immunoglobulin-like domains 
designated D0, D1 or D2. These domains form a V-shaped structure that interact with their HLA class 
I ligand on the target cell.  Although the ligands for the inhibitory KIR have been well characterised, 
uncertainty still exists around some activating KIR ligands. 
 
Figure 2: Interaction of KIR2DL and KIR3DL with HLA class I ligands and the structure of 
KIR2DL4. The general docking mode of KIR2DL and KIR3DL receptors on HLA class I ligands is 
depicted.  Two orthogonal views are shown of KIR2DL1 in complex with HLA-C*04:01 (A and B) 
(30) and KIR3DL1 in complex with HLA-B*57:01 (C and D)  (33).  The monomeric structure of 
KIR2DL4 is shown (E) and the KIR2DL4 tetramer as observed in the crystal lattice (F). The D0, D1 
and D2 domains are noted. (F) The major hinge angles for all KIR-HLA complex structures solved 
to date (29-31, 33). (G) The angular difference in docking position of the D1 and D2 (orthogonal to 
the hinge-angle) for all the complexes solved to date (29-31, 33). The range in angular difference is 
shown. 
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Figure 3: Conservation of the KIR binding footprint to their respective HLA. Footprint of KIR2DL2 
(A), KIR2DS2 (B) and KIR3DL1 (C) overlaid on that of KIR2DL1. For panels A-C conserved 
contacts are coloured gold, unique contacts are coloured by KIR; KIR2DL1 in dark blue, KIR2DL2 
in purple, KIR2DS2 in brown and KIR3DL1 in teal. (D) Conserved KIR binding footprint on HLA. 
Residues contacted across all KIR-HLA complexes are coloured light blue. Of these, the contacts that 
have a conserved interaction with a specific KIR residue are coloured gold. 
 
 
Figure 4: Interaction between KIR and their respective HLA ligands. Interactions between the KIR 
and HLA are coloured by loop for (A, B) KIR2DL2-HLA-C*03:04, (C, D) KIR2DL1-HLA-C*04:01, 
(E, F) KIR2DS2-HLA-A*11:01 and (G, H) KIR3DL1-HLA-B*57:01.  Left-hand panels depict D1 
loops A’-B loop is coloured pink, the C-C’ loop is cyan and the E-F loop is orange.  Right-hand 
panels depict the D2 loops and D1-D2 linker: the D1-D2 linker is coloured green, the B-C loop is 
coloured yellow and the F-F’ hinge loop is coloured wheat.  
 
Figure 5: Involvement of the peptides at the KIR-HLA interface. KIR residues that are involved in 
direct or water mediated peptide contacts are depicted for (A) KIR2DL1-HLA-C*04:01, (B) 
KIR2DL2-HLA-C*03:04, (C) KIR2DS2-HLA-A*11:01 and (D) KIR3DL1-HLA-B*57:01. 
Hydrogen bonds/salt bridges are shown in blue, VDW contacts are shown in red. Panel C shows that 
there is no peptide contact by the KIR in the KIR2DS2/HLA-A*11:01 complex. 
 
 
Figure 6: The structure of CD94-NKG2A in complex with HLA. (A and B) Orthogonal views of 
NKG2A-CD94 in complex with HLA-E (121). (C) The binding footprint of CD94-NKG2A on HLA-
E. The contacts from CD94 are coloured light brown, those to NKG2A are coloured dark brown. 
Contacts to both CD94 and NKG2A are coloured red. (D) Peptide contacts to NKG2A (dark brown) 
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and CD94 (light brown). Of note, the Gln112 on CD94 interposes the peptide, binding between Arg5 
and Phe7. 
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Table 1: Common HLA residues shared as KIR contacts 
 
HLA KIR 
C2a C1 A11 Bw4 KIR2DL1 KIR2DL2 KIR2DS2 KIR3DL1 
   Gly16    Phe9  
Ser11 
His29 
Phe34 
   Arg17    Phe9 
   Gly18    Phe9 
Arg69 Arg69   Arg68 Glu21 
Met70 
  
Gln72 Gln72 Gln72 Gln72 Arg68 Asp72 
Met70 
 Met165 
Arg75 Arg75 Arg75  Phe45 Phe45 Asp72 
Met70 
 
Val76 Val76 Val76 Glu76 Phe45  
Met70 
Asp72 
Phe45 
 
Met70 
Gln71  
Ala167 
Arg79 Arg79 Gly79 Arg79 Phe45 Lys44 
Phe45 
Tyr45 Gly138 
Ser140 
Lys80 Asn80 Thr80 Ile80 Met44 
Ser184 
Glu187 
Gln71 
Lys44 
Ser184 
Tyr45 Leu166 
   Arg83    His278 
Tyr84 Tyr84  Tyr84 Asp183 Asp183  His278 
   Glu89    Trp13 
  Ile142 Ile142   Asp183 His278 
Arg145 Arg145 Arg145 Arg145 Ser133 
Asp135 
Ser133 
Asp135 
Ser133 
Asp135 
Phe181 
Ser228 
Asp230 
Phe276 
Lys146 Lys146 Lys146 Lys146 Tyr105 
Phe181 
Asp183 
Ser184 
 
Tyr105 
Phe181 
Asp183 
Ser184 
 
Tyr105 
Phe181 
Ser184 
 
Tyr200 
Phe276 
Ser279 
Glu282 
Ala149 Ala149 Ala149 Ala149 Tyr105 
Glu106 
Ser132 
Tyr105 
Glu106 
Ser132 
Tyr105 
Glu106 
Ser132 
 
Tyr200 
Glu201 
Ser227 
 
Ala150 Ala150  Ala150 Leu104 Leu104  Tyr200 
Arg151 Arg151 His151 Arg151 Glu106 Glu106 Glu106 Glu201 
peptide      
 Leu7    Leu104 
Tyr105 
  
 Ala8  Ser8  Gln71  Leu166 
β2m       
   Glu36    His32 
 
 
a. C2/KIR2DL1 contacts based on (30); C1/KIR2DL2 on (29); A11/KIR2DS2 on (31) and Bw4/KIR3DL1 on (33) 
but have been refined to 3.8Å.  Salt bridges are coloured red; H-bonds blue. Specificity-defining HLA residues 
are in bold. 
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Table 2: Polymorphic residues among KIR3D molecules 
 KIR3D residuea 
  D0 D1 D2 TM-tail 
3DL1 
-2
0
 
-9
 
2
 
1
8
 
3
1
 
4
4
 
4
7
 
5
4
 
5
8
 
7
5
 
8
6
 
9
2
 
1
3
8
 
1
4
1
 
1
4
5
 
1
6
3
 
1
6
6
 
1
8
2
 
1
9
9
 
2
3
8
 
2
5
6
 
2
8
3
 
3
2
0
 
3
4
3
 
3
7
3
 
*015 L F V V R R V L S R S V G K R P L P P G Q W I C E 
*002                    R      
*007                       V  Q 
*001 S L M    I I                  
*005 S L M    I I          S    L    
*004 S L M  H G I I   L       S    L V Y Q 
3DS1                          
*013  L M     I G   M W   S R  L       
 
a. Table adapted from (54).  Note that the list of KIR3D residues displaying polymorphism is not exhaustive. 
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